Jefferies Financial Group Inc. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 65.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,415 shares of the medical equipment provider’s stock after selling 21,353 shares during the period. Jefferies Financial Group Inc.’s holdings in Zimmer Biomet were worth $1,014,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently made changes to their positions in ZBH. Tacita Capital Inc acquired a new stake in shares of Zimmer Biomet during the second quarter worth about $26,000. Ancora Advisors LLC purchased a new stake in shares of Zimmer Biomet in the 2nd quarter valued at about $29,000. Elevation Wealth Partners LLC lifted its holdings in shares of Zimmer Biomet by 145.9% in the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 229 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zimmer Biomet in the 1st quarter valued at about $44,000. Finally, Parvin Asset Management LLC acquired a new stake in shares of Zimmer Biomet in the 2nd quarter valued at about $47,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.
Insider Activity at Zimmer Biomet
In related news, insider Chad F. Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This trade represents a 4.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is owned by corporate insiders.
Zimmer Biomet Stock Performance
Shares of NYSE ZBH traded down $1.38 during midday trading on Friday, reaching $103.18. 2,517,489 shares of the company were exchanged, compared to its average volume of 2,379,990. The stock has a market cap of $19.53 billion, a P/E ratio of 26.12, a PEG ratio of 2.45 and a beta of 0.50. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $112.54. The stock has a fifty day simple moving average of $95.76 and a 200 day simple moving average of $92.57. The company has a current ratio of 1.46, a quick ratio of 0.79 and a debt-to-equity ratio of 0.49.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. The firm had revenue of $2.06 billion during the quarter, compared to the consensus estimate of $2.04 billion. During the same period in the prior year, the business earned $1.90 EPS. The firm’s revenue was up 3.1% compared to the same quarter last year. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.56 earnings per share for the current fiscal year.
Zimmer Biomet Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s payout ratio is presently 24.30%.
Analysts Set New Price Targets
A number of research analysts recently issued reports on ZBH shares. Barclays raised their price target on Zimmer Biomet from $100.00 to $115.00 and gave the stock an “equal weight” rating in a research note on Monday, November 9th. Canaccord Genuity Group raised their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Stifel Nicolaus set a $125.00 target price on shares of Zimmer Biomet in a report on Wednesday, November 4th. JPMorgan Chase & Co. lifted their target price on shares of Zimmer Biomet from $117.00 to $120.00 and gave the company a “neutral” rating in a report on Thursday, November 5th. Finally, Truist Financial set a $114.00 price target on shares of Zimmer Biomet in a research report on Thursday, November 5th. Seven investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $112.74.
Check Out Our Latest Research Report on ZBH
About Zimmer Biomet
Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.
See Also
- Five stocks we like better than Zimmer Biomet
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
